Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Christopher

Bunick

,

MD, PhD

Associate Professor of Dermatology
Yale University
New Haven
,
Connecticut
,
United States
Councilor Since: June 14, 2024
IPC Councilor
Dr. Christopher Bunick is an Associate Professor of Dermatology specializing in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using X-ray crystallography and cryo-electron microscopy. He sees patients at Yale Dermatology Associates in Middlebury, Connecticut, United States. Dr. Bunick provides care to patients with all dermatologic conditions. Dr. Bunick received his BS degree at Vanderbilt University (Nashville, Tennessee) and his MD and PhD degrees at Vanderbilt University School of Medicine. His PhD research studied the three-dimensional structures of calcium-binding proteins and proteins involved in DNA repair processes (e.g., the skin disease xeroderma pigmentosum). He completed a medical internship, a dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at Yale University School of Medicine (New Haven, Connecticut). He performs laboratory research intending to use X-ray crystallography, cryo-electron microscopy, and biochemistry to understand better the structure-function relationship of proteins involved in normal and diseased skin and dermatologic therapeutics.
Last Updated:
07/10/2024

Areas of Interest

Understanding the mechanisms of action of psoriasis therapeutics at the biochemical and structural level; correlating physicochemical properties of psoriasis therapeutics with clinical efficacy and safety outcomes

Languages Spoken

English

What's New

Videos Now Available from the IPC Symposium at SID Chicago

Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.

WATCH NOW

Wednesday, June 17, 2026

Take Ten: Mio Nakamura – Psoriasis and Mental Health

Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.

WATCH NOW

Thursday, June 11, 2026